CN109761977B - 一种黄精生物碱c及其制备方法与应用 - Google Patents
一种黄精生物碱c及其制备方法与应用 Download PDFInfo
- Publication number
- CN109761977B CN109761977B CN201910162541.7A CN201910162541A CN109761977B CN 109761977 B CN109761977 B CN 109761977B CN 201910162541 A CN201910162541 A CN 201910162541A CN 109761977 B CN109761977 B CN 109761977B
- Authority
- CN
- China
- Prior art keywords
- polygonatum
- alkaloid
- column
- methanol
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZTNBSFMIFOLVCM-UHFFFAOYSA-N 20S-Dimethylamino-3alpha-methoxypregn-5-ene Natural products C12CCC3(C)C(C(C)N(C)C)CCC3C2CC=C2C1(C)CCC(OC)C2 ZTNBSFMIFOLVCM-UHFFFAOYSA-N 0.000 title claims abstract description 17
- PZZXYDQKZIGACT-UHFFFAOYSA-N 5-hydroxyskytanthine Natural products C1N(C)CC(C)C2(O)C1C(C)CC2 PZZXYDQKZIGACT-UHFFFAOYSA-N 0.000 title claims abstract description 17
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 title claims abstract description 17
- 241000756042 Polygonatum Species 0.000 title abstract description 65
- 238000002360 preparation method Methods 0.000 title description 9
- 229930013930 alkaloid Natural products 0.000 claims abstract description 34
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 11
- 241000037831 Polygonatum sibiricum Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 6
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims 4
- 229920005654 Sephadex Polymers 0.000 claims 2
- 239000012507 Sephadex™ Substances 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- GOENJWUGVSLZDQ-JBWWEBJPSA-N [7-[(z)-2-methylbut-2-enoyl]oxy-5,6,7,8-tetrahydro-3h-pyrrolizin-1-yl]methyl (e)-2-(hydroxymethyl)but-2-enoate Chemical compound C1C=C(COC(=O)C(\CO)=C\C)C2C(OC(=O)C(\C)=C/C)CCN21 GOENJWUGVSLZDQ-JBWWEBJPSA-N 0.000 description 7
- SZCHXNLVRKQEGO-XKDXWZMYSA-N alkaloid b Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1C[C@H](O)C2=CC1=C3OCO1 SZCHXNLVRKQEGO-XKDXWZMYSA-N 0.000 description 7
- PMBXAKHNZRLXJE-UHFFFAOYSA-N comosine Natural products COC1CC23C(CCN2CCCc2cc4OCOc4cc32)C=C1 PMBXAKHNZRLXJE-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 102000055102 bcl-2-Associated X Human genes 0.000 description 5
- 108700000707 bcl-2-Associated X Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000004262 preparative liquid chromatography Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000002027 dichloromethane extract Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- FQSOULCUJFWKPP-UHFFFAOYSA-N kinganone Natural products O=C1CCCN2C(COCCCC)=CC=C21 FQSOULCUJFWKPP-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000003771 C cell Anatomy 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- -1 alkaloid compounds Chemical class 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 229930002600 steroidal saponin Natural products 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- JJBKVCQUFIBRFK-UHFFFAOYSA-N chloromethane;methanol Chemical compound OC.ClC JJBKVCQUFIBRFK-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000010576 medium-pressure preparative liquid chromatography Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- WBGPNPZUWVTYAA-UHFFFAOYSA-N methane;dihydrochloride Chemical compound C.Cl.Cl WBGPNPZUWVTYAA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229930187913 polygonatine Natural products 0.000 description 1
- BOZPTHCSOXMEHQ-UHFFFAOYSA-N polygonatine B Natural products O=C1CCCN2C(COCC)=CC=C21 BOZPTHCSOXMEHQ-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003233 pyrroles Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域
本发明属于中药开发利用领域,具体涉及一种黄精生物碱C及其制备方法与应用。
背景技术
黄精是2016年国家卫计委最新颁布的既是食品又是药品的中药之一。黄精作为一种传统名贵中药,具有补气养阴,健脾,润肺,益肾功效,用于脾胃气虚,体倦乏力,胃阴不足,口干食少,肺虚燥咳,劳嗽咳血,精血不足,腰膝酸软,须发早白,内热消渴等病症。传统认为黄精如果不炮制或炮制不合理,很可能就会引起某些副作用,临床上不应使用生黄精而应用制黄精,通过炮制,一方面可制其毒副作用,消除麻味,减轻对咽喉的刺激,另一方面可提高黄精的临床疗效,增强药物补脾润肺、益肾的作用。炆黄精是江西建昌帮最具有代表性的饮片之一,炆法存在历史超过400年。传统的建昌帮制备炆黄精是选择华东地区的姜形黄精药材,采用传统的炆制方法制备,是具有鲜明江西特色的中药饮片。
黄精含有多种化学成分,主要包括多糖、甾体皂苷、三萜、生物碱、木脂素、黄酮、植物甾醇及挥发油等,其中多糖和甾体皂苷类成分在黄精中量较大,为其主要药效成分,具有降血糖、降血脂抗炎、抗肿瘤、调节免疫等作用。现代临床常用于治疗糖尿病、动脉硬化等疾病。黄精属植物中所含生物碱量较低,目前发现种类较少,从滇黄精和黄精中共分离得到5个生物碱类化合物,主要为吲哚嗪类生物碱,分别为polygonatine A、polygonatine B(SunL R,Li X,Wang S X.Two new alkaloids from the rhizome of polygonatum sibiricum[J].J Asian Nat Prod Res,2005,7(2):127-130.)、kinganone(Wang Y F,Lu C H,Lai GF,et al.A new indolizinone from polygonatum kingianum[J].Planta Med,2003,69(11):1066-1068.)、k-trans-p-coumaroyloctopamine(王易芬,穆天慧,陈纪军,等.滇黄精化学成分研究[J].中国中药杂志,2003,28(6):524-527.)和腺苷(Son K H,Do J C,KangSS.Isolation of adenosine from the rhizomes of Polygonatum sibiricum[J].ArchPharm Res,1991,14(2):193-194.),以及从滇黄精中分离得到3-丁氧甲基-5,6,7,8-四氢-8-吲哚哩嗪酮(朱艳玲.两种药用植物的化学成分研究[D].昆明:昆明医学院,2008.)。结构式如下所示:
发明内容
针对现有技术的问题,本发明提供了一种从炆黄精中提取到的新的黄精生物碱C及其制备方法和黄精生物碱在预防、治疗抗阿尔茨海默症药物中的应用。
本发明具体技术方案如下:
一种黄精生物碱C及其药学上可成的盐,具有如下结构:
本发明另一目的在于提供上述黄精生物碱C的制备方法,包括如下步骤:
(1)取多花黄精的干燥根茎,炆法炮制后,乙醇溶液提取、二氯甲烷萃取、浓缩制得浸膏;
具体的操作为:取多花黄精的干燥根茎,切厚片,经建昌帮传统炮制方法炆法进行炮制,50℃干燥,粉碎成粗粉,70%乙醇浸泡过夜,加热回流提取2h,滤过,浓缩至小体积,二氯甲烷萃取,浓缩至浸膏;
(2)将二氯甲烷浸膏部分用甲醇溶解后,干法上硅胶柱,以二氯甲烷-甲醇(优选体积比为20:1)等度洗脱1-5个柱体积(优选2.5个柱体积),取干柱部分,自下而上切成5份(优选平均切分),命名为F6~F10,取第1份F6部分上硅胶柱,以石油醚-乙酸乙酯(优选以体积比20:1~1:1线性洗脱)洗脱1-5个柱体积(优选3个柱体积),依次得22个洗脱组分,命名为F6-a~F6-v,取第20个洗脱组分F6-t上硅胶柱,以三氯甲烷-甲醇(优选以体积比为200:1、100:1、70:1、50:1、20:1、10:1的三氯甲烷-甲醇为洗脱剂依次洗脱,各洗脱1-5个柱体积,优选3个柱体积),依次得7个洗脱组分,命名为F6-t-1~F6-t-7,取第1洗脱组分F6-t-1上凝胶柱(优选Sephadex LH-20),以甲醇洗脱,依次得两个洗脱组分,命名为F6-t-1-1和F6-t-1-2,取组分F6-t-1-2经高效制备液相色谱制备,得到黄精生物碱C。优选反相高效制备液相色谱条件为色谱柱:YMC-Pack ODS-A(250×20mm,S-5um,12nm)流动相:甲醇:水=37:63(V/V),流速7mL/min。
本发明另一目的在于提供黄精生物碱及其药学上可成的盐在制备治疗或预防阿尔茨海默症药物中的应用,所述黄精生物碱结构如下:
阿尔茨海默症(Alzheimer’s disease,AD,又称老年痴呆)是一种中老年常见的以渐行性记忆力减退、认知功能障碍、人格改变为特征的中枢神经系统退行性疾病。全球老年痴呆症病人已经超过4000万,随着世界人口老龄化的加剧,患者将持续增加,预计到2050年老年痴呆症患者人数将超过1.5亿,也就是85岁以上老人,每2人中就有1个老年痴呆症患者,由此将带来诸多的社会和经济问题,因此对AD的防治已成为十分迫切的社会与医学问题。目前治疗药物种类繁多,但多为对症治疗,且疗效不确切、特异性不强、毒副作用大、不易透过血脑屏障等,限制了其临床应用,因此开发高效低毒老年性痴呆防治药物一直是国内外医药界的研究热点。本发明从炆黄精中分离得到系列生物碱类成分,特别是得到一种新的黄精生物碱C,并对这些成分药理活性进行了研究,结果表明,黄精生物碱A、B、C具有很好的预防、治疗抗老年痴呆药物中的应用。
附图说明
图1为检测波长为210nm和300nm黄精生物碱C的HPLC制备色谱图(tR=42.1min)。
具体实施方式
以下通过实施例说明本发明的具体步骤,但不受实施例限制。
在本发明中所使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实例并参照数据进一步详细描述本发明。应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
实施例1炆黄精中生物碱的制备
1.药材来源及炆黄精制备
本发明所用多花黄精药材为百合科植物多花黄精的干燥根茎,购自江西省樟树市药材市场,并经江西中医药大学药学院付小梅副教授鉴定,且留存标本在江西省药品检验检测研究院中药标本室。
炆法黄精:取净黄精药材,用清水漂一天,取出,沥干,放入炆药罐内炆24h,至药熟透汁尽,取出,50℃干燥,加20%黄酒喷洒均匀,闷润,待酒吸尽,蒸制4h,焖一夜,取出,放入烘箱内50℃干燥,备用。
2.仪器与试剂
岛津2010系列高效液相色谱仪(日本岛津公司),检测器均为PDA检测器,色谱柱为YMC(10μm,150×4.6mm和10μm,250×4.6mm);Aglient 1260液相色谱仪(美国安捷伦科技有限公司);岛津20-AD型制备高效液相色谱仪,制备柱为YMC(10μm,250×20mm);Buchi中压液相制备色谱仪(瑞士步琪公司);C18反相填料为日本YMC产品;Sephadex LH-20(瑞典Amersham Biosciences公司);A EYELA SB-1000旋转蒸发仪(日本EYELA公司);电热恒温水浴锅(上海跃进医疗器械厂);1H NMR(600MHz)和13C NMR(150MHz)谱用Varian UNITYINOVA600型超导核磁共振仪测定,以氘代试剂作标定;Micromass ZabSpec质谱仪(美国Micromass公司);Sartorius BP211D型电子天平(德国赛托利斯集团);UV用UV-260紫外分光光度计(日本岛津公司)测定,溶剂为甲醇;柱色谱硅胶(100~200目)、薄层色谱硅胶(青岛海洋化工厂);实验中所用试剂(石油醚、二氯甲烷、氯仿、乙酸乙酯、正丁醇、甲醇、95%乙醇、无水乙醇、硫酸、甲酸等)为天津市富宇精细化工有限公司产品,均为分析纯;水为娃哈哈纯净水,氘代试剂DMSO-d6(美国剑桥公司CIL);色谱乙腈和甲醇为上海安谱科学仪器有限公司产品。
3.生物碱的制备与结构鉴定
3.1多花黄精的干燥根茎30kg经江西古汉精制中药饮片厂按照江西建昌帮传统炮制方法——炆法炮制后得到17kg炆黄精炮制品。取炆黄精药材粉碎,用10倍量70%乙醇浸泡1h,加热回流提取2次,每次2h,滤过,提取液合并浓缩至20L,用两倍体积的二氯甲烷分别萃取三次。萃取液分别减压浓缩至干,得二氯甲烷浸膏210g。
3.2二氯甲烷浸膏(210g)用适量甲醇溶解后,用1:1.5的硅胶拌样,干法上硅胶(100-200目)柱,以二氯甲烷-甲醇(20:1,V/V)洗脱2.5个柱体积,依次接下5份2000ml洗脱液F1~F5及自下而上平均切得干柱组分5份F6~F10。F6(60.8g)上硅胶柱,以石油醚-乙酸乙酯(20:1~1:1,V/V)洗脱3个柱体积,得22个组分F6-a~F6-v。F6-t(3.15g)上硅胶柱,以三氯甲烷-甲醇(200:1、100:1、70:1、50:1、20:1、10:1,V/V)为洗脱剂依次洗脱3个柱体积,得组分F6-t-1~F6-t-7,F6-t-1(357mg)上Sephadex LH-20凝胶柱,甲醇洗脱,得F6-t-1-1~F6-t-1-2,F6-t-1-2(177mg)经高效制备液相色谱制备,色谱条件为:色谱柱:YMC-PackODS-A(250×20mm,S-5um,12nm)流动相:甲醇-水(37:63,V/V),流速7mL/min,得到化合物Ⅰ*(28.2mg)(新化合物),检测波长为210nm和300nm的HPLC制备色谱图如1所示,收集保留时间为42.1min处的色谱峰进行结构鉴定。F6-v(830mg)上Sephadex LH-20凝胶柱,甲醇洗脱,得F6-v-1~F6-v-2,其中F6-v-2(308mg)经高效制备液相色谱制备,色谱条件为:色谱柱:YMC-Pack ODS-A(250×20mm,S-5um,12nm)流动相:甲醇-水(11:89,V/V),流速7mL/min,得到化合物Ⅱ(50.2mg)。F6-r(13.1g)上硅胶柱,以石油醚-乙酸乙酯(10:1~1:1,V/V)洗脱,得9个组分F6-r-1~F6-r-9)。F6-r-6(2.5g)经中压制备液相色谱,以甲醇-水(10:90~80:20,V/V)梯度洗脱,得到10个组分F6-r-6-1~F6-r-6-10。F6-r-6-7(64mg)经高效制备液相色谱制备,色谱条件为:色谱柱:YMC-Pack ODS-A(250×20mm,S-5um,12nm)流动相:甲醇-水(32:68),流速7mL/min,得到化合物Ⅲ(30.3mg)。
4.结构鉴定
化合物Ⅰ:淡黄色油状物(甲醇)。[a]20D-9.5(c 0.24,MeOH);UV(MeOH)max(loge):293(0.3855)nm;HRESI-MS m/z:272.0948[M–H]-(calcd for C15H15NO4,272.0923);1H NMR(600MHz,MeOD)and 13C NMR(150MHz,MeOD)。数据见表1。
通过HRESI-MS m/z:272.0948[M–H]-推测分子离子峰为273,为奇数,且谱中给出许多偶数质荷比碎片离子峰,推测分子式为:C15H15NO4,示该化合物为生物碱类化合物,分子量为273。1H NMR谱中,有两个相互偶合的芳质子信号6.88ppm(1H,J=4.1Hz)和6.26ppm(1H,J=4.1Hz),1C NMR谱中有8个芳碳信号,其中4个为季碳,以及HRESI-MS中有多个偶数质荷比碎片离子峰(m/z(-):146,134,118),示一个芳环部分为取代的吡咯环:环上两个芳质子信号呈双峰,且偶合常数为J=4.1Hz,示该两个芳质子位于吡咯环的β位,其α位均被取代。另外一个芳环部分为取代的呋喃环:环上两个芳质子信号呈双峰,且偶合常数为J=3.6Hz,示该两个芳质子位于呋喃环的β位,其α位均被取代。
1H NMR谱中,有一个醛基氢单峰信号9.52ppm,示该化合物为醛类成分。1H NMR谱中,有5个亚甲基质子信号,其中吡咯环上3个亚甲基质子信号4.56ppm(2H,s)、4.10ppm(2H,dd,J=6.5,5.3Hz)、2.22ppm(2H,dd,J=6.7,5.3Hz)。在1H-1HCOSY谱中,4.10ppm的质子与2.22ppm的质子相关;HMBC谱中,4.56ppm的质子除与另外2个亚甲基碳相关外,还与132.9ppm、136.2ppm两个芳环上的季碳相关,表明该亚甲基连在吡咯环的α位。1H NMR谱中还有2个亚甲基质子信号4.60ppm(2H,s)和4.82ppm(2H,s),在HMQC谱中,与4.60ppm(2H,s)亚甲基相关的碳为114.5ppm和113.3ppm,表明该亚甲基为连氧亚甲基;结合HMBC谱,示该亚甲基连于吡咯环的另一α位。另一个亚甲基质子信号4.82ppm(2H,s)相关的碳为113.1ppm和124.6ppm,表明该亚甲基为连氧亚甲基;结合HMBC谱,示该亚甲基连于呋喃环的α位。
综合分析1H NMR、13C NMR、1H-1H COSY、HMQC、HMBC谱,将该化合物的氢谱和碳谱数据予以归属(见表1)。综上所述,确认该化合物为:
3-(3'-furaldehyde-5'-methoxymethyl)-5,6,7,8-tetrahydroindolizin-8-one,为未见文献报道的新化合物。命名为黄精生物碱C,结构如下:
表1化合物Ⅰ的核磁氢谱和碳谱数据
Recorder in MeOD。
化合物Ⅱ:黄精生物碱A:白色粉末(甲醇)。ESIMS m/z:188[M+Na]+,164[M-H]-;显示其分子量为165,结合核磁共振谱推测其分子式为C9H11NO2。
1H-NMR(600 MHz,MeOD)δ:6.92(1H,d,J=4.2 Hz,H-1),6.24(1H,d,J=4.2 Hz,H-2),4.61(2H,s,H-10),4.15(2H,m,H-5),2.57(2H,m,H-7),2.27(2H,td,J=5.2,1.2 Hz,H-6)。13C-NMR(150 MHz,MeOD)δ:115.0(C-1),111.8(C-2),140.1(C-3),43.6(C-5),24.6(C-6),36.9(C-7),190.5(C-8),132.4(C-9),56.6(C-10)。上述数据与文献(Sun L R,Li X,Wang S X.Two new alkaloids from the rhizome of Polygonatum sibiricum[J].Journal of Asian Natural Products Research,2005,7(2):127-130.)报道基本一致,故鉴定化合物Ⅱ为黄精生物碱A。
化合物Ⅲ:黄精生物碱B:淡黄色油状物(甲醇)。ESIMS m/z:216[M+Na]+,192[M-H]-;显示其分子量为193,结合核磁共振谱推测其分子式为C11H15NO2。1H-NMR(600MHz,MeOD)δ:6.97(1H,d,J=4.0Hz,H-1),6.30(1H,d,J=4.0Hz,H-2),4.55(2H,s,H-10),4.16(2H,t,J=7.0Hz,H-5),3.57(2H,q,J=7.0Hz,H-11),2.61(2H,t,J=6.4Hz,H-7),2.27(2H,m,H-6),1.25(3H,t,J=7.0Hz,H-12)。13C-NMR(150MHz,MeOD)δ:114.5(C-1),112.6(C-2),137.0(C-3),43.6(C-5),24.5(C-6),36.8(C-7),190.2(C-8),132.6(C-9),64.6(C-10),66.7(C-11),15.6(C-12)。上述数据与文献(Sun L R,Li X,Wang S X.Two new alkaloids from therhizome of Polygonatum sibiricum[J].Journal of Asian Natural ProductsResearch,2005,7(2):127-130.)报道基本一致,故鉴定化合物Ⅲ为黄精生物碱B。
实施例3生物碱单体成分对神经细胞损伤的保护实验
1.单体成分对Aβ25~35所致AD细胞模型的保护作用
1.1实验材料
PC12细胞购置于中国科学院上海细胞库;Aβ25~35(Sigma,053M4804V);MTT细胞增殖及毒性检测试剂盒(Solarbio,20150708);改良型RPMI Medium 1640培养基(Gibco,8115154);胎牛血清(Gibico,1095513);顶级马血清(江苏恩莫阿塞生物技术有限公司,WPX141002);多聚赖氨酸(博士德生物,NO.10F03A03);PBS(Solarbio,20160825)。AnnexinV-FITC/Hoechst33342细胞凋亡检测试剂盒(贝博生物,批号:BB130082)。β-Actin MouseMonoclonal Antibody(affinity,T0022);Bax Antibody(Cell Signaling,0012);Anti-Bcl2antibody(abcam,ab7973);Anti-Caspase-3(abcam,ab32351)。
1.2实验仪器
CO2培养箱(SANYO,MCO-750);酶标仪(Biotek,ELx800);超净工作台(苏州净化设备厂);高速冷冻离心机(AllegraTMX-12R,Beckman Coulter);倒置显微镜(Leica,DMI3000B);型电热压力蒸汽灭菌器(上海博讯实业医疗设备厂,YXQ-LS-SII);水浴锅(江苏省金坛市医疗仪器厂,HH-S);移液枪(GILSON,法国);In Cell Analysis 6000(GE,美国)。电泳仪、垂直电泳槽、转移槽(Bio-Rad);EC3凝胶成像系统(UVP,美国);多标记检测仪(VITOR 1420,Perkin Elmer)。1.3实验方法
1.3.1对Aβ25~35损伤所致PC12细胞存活率的影响
取对数生长期PC12神经细胞以4×105密度接种于96孔板,100μL/孔,分为空白组,模型组,黄精生物碱组,每组5个复孔。孵箱内培养24h。吸出培养基,给药组加入含药培养基100μL/孔,黄精生物碱终浓度为20、40、80μmol/L;空白组和模型组加入空白培养基100μL/孔。模型组和给药组,每孔加入2μL的Aβ1mmol/L,终浓度为20μmol/L。继续培养48h。每孔加入20μL的MTT,培养4h。吸去培养基,每孔加入150μLDMSO,在摇床上摇匀10min,酶标仪570nm处测OD值。
1.3.2对Aβ25~35诱导的PC12细胞凋亡率的影响
收集对数生长期的PC12细胞,调整细胞密度为1×104/孔,96孔板中加入150μL/孔。分设空白组、模型组、黄精生物碱组,黄精生物碱终浓度为40、80μmol/L,每组设5个复孔。在5%CO2,37℃细胞培养箱中孵育12h,使细胞单层贴壁,此时加入培养基、药物组稀释到相应浓度的培养基每孔100μL,24h后模型组和给药组加入造模药Aβ25~35,使其终浓度为30μmol/L;48h后吸出培养基,PBS清洗3遍,在400μL×Annexin V结合液中加入5μL AnnexinV-FITC染色液和10μLPI染色液后轻轻混匀,以50μL/孔加入培养板,2-8℃避光,孵育15min;加入Hoechst33342,每孔2μL,常温避光孵育5min;用In Cell Analysis 6000进行拍照分析。
1.3.3对Aβ25~35所致AD细胞模型凋亡相关蛋白Bcl-2、Bax、Caspase-3表达量的影响(WB法)
取对数生长期PC12细胞,轻吹打至完全脱落,离心去上清液。培养基重悬细胞后,以4×105个/ml的浓度接种于培养皿中;设8个组分别为空白、模型、黄精生物碱C、A、B终浓度40、80μmol/L,每组2个复孔,37℃,5%CO2恒温培养箱中培养12小时;去上清液,空白组和模型组每个培养皿加入100μl的空白培养基,其余各给药组加入相应的含药培养基。37℃,5%CO2恒温培养箱中继续培养24小时;模型组和各个给药组加入Aβ25~35使其终浓度为30μmol/L,继续培养24h;吸去上清液,用PBS清洗三遍,每个培养皿加入1ml含10%PMSF的蛋白提取试剂,4℃裂解15min;在4℃,14000g离心10min;吸取细胞上清液转移至新的EP管中,于-20℃储存备用;用BCA试剂盒做蛋白定量(OD570);SDS-PAGE电泳及蛋白转移;免疫反应检测目的蛋白。
1.4实验结果
实验结果见表2、表3、表4。通过SPSS22.0分析,与空白组相比较,模型组细胞存活性明显下降,早期凋亡率、死亡率明显上升,抗凋亡因子Bcl-2的表达下降,促凋亡因子Bax和Caspase-3的表达降低,说明造模成功;从表3可看出与模型组比较,黄精生物碱C、黄精生物碱A、黄精生物碱B组在40、80μmol/LOD值明显上升,提示以上化合物可明显提高Aβ25~35损伤所致的PC12细胞存活率;从表4可看出,与模型组比较,黄精生物碱C、黄精生物碱A、黄精生物碱B在40、80μmol/L死亡率和早期凋亡率明显降低,存活率明显增高,提示黄精生物碱C、黄精生物碱A、黄精生物碱B可减少Aβ25~35所致神经细胞凋亡;从表6可看出,与模型组比较,黄精生物碱C、黄精生物碱A、黄精生物碱B在40、80μmol/L可提高抗凋亡因子Bcl-2的表达,同时可降低促凋亡因子Bax和Caspase-3的表达,提示黄精生物碱C、黄精生物碱A、黄精生物碱B对神经细胞凋亡有明显的保护作用。
备注:与模型组比较*P<0.05,**P<0.01;
注:与模型组比较*P<0.05。
表4不同浓度炆黄精中生物碱单体成分对Aβ25-35所致AD细胞模型的Bcl-2、
注:与模型组比较*P<0.05。
2.单体成分对Aβ25~35所致的原代海马神经元细胞AD模型存活率的影响
2.1实验方法
提取乳鼠海马细胞并进行培养,MAP2/FITC染色法对海马细胞进行鉴定。调整细胞混悬液浓度,接种于预先用0.1%多聚赖氨酸包被过夜的96孔板中加入150μl/孔,调整细胞密度为1×104/孔。分设空白组、模型组、黄精生物碱组,黄精生物碱终浓度为20、40、80μmol/L,每组设4个复孔;在5%CO2,37℃细胞培养箱中培养至第7天,使细胞单层贴壁,此时加入生长培养基、稀释到相应浓度的山奈酚和槲皮素培养基每孔100μ、模型组和给药组加入造模药Aβ25~35,使其终浓度为20μmol/L;5%CO2,37℃条件下孵育48h;每孔加入50μl,MTT(5mg/ml,即0.5%MTT),继续培养4h;小心吸去孔内培养液,每孔加入100μlDMSO,置摇床上低速振荡10~15min,使结晶充分溶解。在酶标仪上选择570nm波长测量各孔OD值。
2.2实验结果
结果见表5。通过SPSS22.0分析,模型组与空白组比较OD值明显下降,说明造模成功;与模型组比较,黄精生物碱C、黄精生物碱A、黄精生物碱B在40、80μmol/LOD值明显上升,提示以上化合物对Aβ25~35所致的原代海马神经元细胞有明显的保护作用。
备注:与模型组比较*P<0.05,**P<0.01。
3.小结
以上结果说明,上述炆黄精中三个生物碱单体对Aβ损伤的PC12神经细胞和海马神经元细胞都有保护作用。提示炆黄精中的生物碱类成分是炆黄精抗老年痴呆的活性成分。
Claims (4)
2.如权利要求1所述黄精生物碱C的制备方法,包括如下步骤:
(1)取多花黄精的干燥根茎,炆法炮制后,70%乙醇溶液提取、二氯甲烷萃取、浓缩制得浸膏;
(2)将浸膏用甲醇溶解后,干法上硅胶柱,以二氯甲烷-甲醇等度洗脱,二氯甲烷与甲醇的体积比为20:1,洗脱1-5个柱体积,取干柱部分,自下而上切成5份,取第1份上硅胶柱,以石油醚-乙酸乙酯线性梯度洗脱,所述线性洗脱梯度为体积比20:1~1:1的石油醚-乙酸乙酯,洗脱1-5个柱体积,依次得22个洗脱组分,取第20个洗脱组分上硅胶柱,以二氯甲烷-甲醇洗脱,二氯甲烷与甲醇体积比为200:1、100:1、70:1、50:1、20:1、10:1的二氯甲烷-甲醇溶液,依次各洗脱1-5个柱体积,依次得7个洗脱组分,取第1洗脱组分上凝胶柱Sephadex LH-20,以甲醇洗脱,依次得2个洗脱组分,取第2洗脱组分经反相高效制备液相色谱制备,色谱柱:YMC-Pack ODS-A,250×20mm,S-5μm,12nm,流动相:甲醇:水=37:63,流速7mL/min,得到黄精生物碱C。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910162541.7A CN109761977B (zh) | 2019-03-05 | 2019-03-05 | 一种黄精生物碱c及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910162541.7A CN109761977B (zh) | 2019-03-05 | 2019-03-05 | 一种黄精生物碱c及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109761977A CN109761977A (zh) | 2019-05-17 |
CN109761977B true CN109761977B (zh) | 2020-07-17 |
Family
ID=66457679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910162541.7A Active CN109761977B (zh) | 2019-03-05 | 2019-03-05 | 一种黄精生物碱c及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109761977B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116514916B (zh) * | 2023-06-26 | 2023-09-08 | 江西省药品检验检测研究院 | 一种吲哚生物碱化合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628694A (zh) * | 2004-08-23 | 2005-06-22 | 吴燊荣 | 黄精多糖的用途之二 |
CN1686418A (zh) * | 2005-04-26 | 2005-10-26 | 张玉良 | 一种可防治老年痴呆病和帕金森病的天然药物 |
CN103071048A (zh) * | 2013-02-07 | 2013-05-01 | 贵州神奇投资有限公司 | 一种治疗阿尔茨海默病的中药组合物及其制备方法 |
TW201524504A (zh) * | 2013-12-18 | 2015-07-01 | Hsiang-Ru Lin | 高異黃酮類、香豆素及其衍生物作爲製備細胞核受器調節劑及dpp4抑制劑之用途 |
CN106109536A (zh) * | 2016-08-03 | 2016-11-16 | 姜广坤 | 用于神经退行性疾病或神经再生的中药组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2761108A1 (en) * | 2009-04-21 | 2010-10-28 | Novartis Ag | Heterocyclic compounds as mek inhibitors |
WO2012172093A1 (en) * | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
-
2019
- 2019-03-05 CN CN201910162541.7A patent/CN109761977B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628694A (zh) * | 2004-08-23 | 2005-06-22 | 吴燊荣 | 黄精多糖的用途之二 |
CN1686418A (zh) * | 2005-04-26 | 2005-10-26 | 张玉良 | 一种可防治老年痴呆病和帕金森病的天然药物 |
CN103071048A (zh) * | 2013-02-07 | 2013-05-01 | 贵州神奇投资有限公司 | 一种治疗阿尔茨海默病的中药组合物及其制备方法 |
TW201524504A (zh) * | 2013-12-18 | 2015-07-01 | Hsiang-Ru Lin | 高異黃酮類、香豆素及其衍生物作爲製備細胞核受器調節劑及dpp4抑制劑之用途 |
CN106109536A (zh) * | 2016-08-03 | 2016-11-16 | 姜广坤 | 用于神经退行性疾病或神经再生的中药组合物 |
Non-Patent Citations (3)
Title |
---|
3种药用黄精的化学成分及药理活性研究进展;陈辉 等;《中草药》;20150812;第46卷(第15期);第2329-2338页 * |
A new indolizinone from Polygonatum kingianum;Yi-Fen Wang et al.;《Planta Medica》;20030810;第69卷(第11期);第1066-1068页 * |
Total synthesis of two novel 5,6,7,8-tetrahydroindolizine alkaloids, polygonatines A and B;Andrew Dinsmore et al.;《Organic & Biomolecular Chemistry》;20060210;第6卷(第4期);第1032-1037页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109761977A (zh) | 2019-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105294720B (zh) | 一种二聚色酮生物碱类化合物及其制备方法和应用 | |
CN105198854B (zh) | 一种具有神经保护作用的异戊烯基化黄酮类化合物的制备方法及应用 | |
CN102861112B (zh) | 海滨锦葵木脂素提取物、其制备方法及其应用 | |
Si et al. | Isolation and characterization of phellodendronoside A, a new isoquinoline alkaloid glycoside with anti-inflammatory activity from Phellodendron chinense Schneid | |
CN108997296B (zh) | 几种异戊烯基二氢茋和异戊烯基黄酮的结构和用途 | |
CN105131008B (zh) | 一种具有抗肝癌活性的异戊烯基化黄酮类化合物的制备方法及其应用 | |
CN109761977B (zh) | 一种黄精生物碱c及其制备方法与应用 | |
CN110357847B (zh) | 一种异黄烷类化合物及其制备方法和用途 | |
CN104447656B (zh) | 一种九里香香豆素及其提取方法 | |
CN109456163B (zh) | 一种具有对称结构的环烯酮类化合物及其制备方法和应用 | |
CN110507662B (zh) | 一种黄精甾体皂苷元及其制备方法与应用 | |
Fu et al. | Chemical constituents of the antiulcer purified fractions of Lindera reflexa Hemsl. and its quantitative analysis | |
CN114349723B (zh) | 多烯炔类化合物及其制备方法和应用 | |
CN113620912B (zh) | 一种呋喃酮化合物及其制备方法与应用 | |
JP6828883B2 (ja) | リグナン系化合物を含む食品組成物 | |
CN100590119C (zh) | 一种抗肿瘤化合物红波罗花碱a及其制备方法和应用 | |
CN110396076B (zh) | 一种异戊烯基化黄酮类化合物及其制备方法和应用 | |
CN103739657B (zh) | 一种油茶皂苷化合物、其制备方法、应用及其制备的抗肿瘤药物 | |
CN111067924A (zh) | 一种具有抑制醛糖还原酶活性的琼花果实总木脂素提取物及其活性成分和用途 | |
CN110563563A (zh) | 一种查耳酮类化合物及其制备方法和用途 | |
CN112047887B (zh) | 一种宽筋藤酰胺及其制备方法与应用 | |
CN118164933B (zh) | 马齿苋中一种呋喃类新化合物及其提取分离方法与用途 | |
CN118666662B (zh) | 环聚酮-萜类加合物、制备方法及其应用 | |
CN110526809B (zh) | 一种查耳酮类化合物及其制备方法和用途 | |
CN109180696B (zh) | 环烯酮类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |